Biomarkers in Multiple Myeloma

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT ETIENNE · Feb 17, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on understanding the connection between multiple myeloma (a type of blood cancer) and the risk of developing blood clots, known as venous thromboembolism (VTE). Researchers want to identify specific biological markers that could help predict which patients are more likely to experience these complications, especially in those newly diagnosed with multiple myeloma who are starting treatment. This is important because having blood clots can affect how well patients respond to their cancer treatment.

To participate in the trial, individuals must be between 65 and 74 years old, have a confirmed diagnosis of newly diagnosed multiple myeloma that requires treatment, and be able to provide written consent. However, pregnant women, those with legal guardianship issues, or individuals whose health is declining may not be eligible to join. Participants can expect to contribute to important research that may improve understanding and management of multiple myeloma and associated risks, ultimately helping future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient affiliated to a social security regimen or beneficiary of the same
• • Signed written informed consent form
• • Confirmed diagnosis of de novo multiple myeloma, non-previously treated and requiring treatment.
• Exclusion Criteria:
• • Pregnant women
• • Patient under guardianship or deprived of his liberty or any condition that may affect the patient's ability to understand and sign the informed consent
• • Refusing participation
• • Patient whose follow-up or life expectancy is less than 6 months.